2024 SABCS Posters

The molecules presented are investigational. Safety and efficacy have not been established.

BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Locally Advanced or Metastatic Breast Cancer and other Solid Tumor: Updated resules from a Phase 1 study.